SAB Biotherapeutics (SABS) Retained Earnings (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Retained Earnings data on file, last reported at -$129.8 million in Q1 2026.

• Quarterly Retained Earnings changed 0.34% year-over-year to -$129.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$129.8 million (changed 0.34% YoY) and the FY2025 annual result came in at -$110.9 million, down 171.18% from the prior year.
• Retained Earnings eased to -$129.8 million in Q1 2026, from -$110.9 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $157.0 million in Q2 2025 to a low of -$129.8 million in Q1 2026.
• A 5-year average of -$23.1 million and a median of -$62.1 million in 2023 frame the typical range for Retained Earnings.
• The widest YoY moves for Retained Earnings: up 943.01% in 2022, down 316.28% in 2022.
• Tracing SABS's Retained Earnings over 5 years: stood at -$47.9 million in 2022, then plunged by 88.14% to -$90.1 million in 2023, then jumped by 272.98% to $155.8 million in 2024, then tumbled by 171.18% to -$110.9 million in 2025, then fell by 17.05% to -$129.8 million in 2026.
• The last three Retained Earnings figures came in at -$129.8 million (Q1 2026), -$110.9 million (Q4 2025), and -$94.0 million (Q3 2025), per Business Quant data.